Kungekudala ngemuva kokuthi u-Abbott ephothule ukulethwa kwezivivinyo zama-antigen ezisheshayo eziyizigidi eziyi-150 kuhulumeni wobumbano ukuze zisatshalaliswe kabanzi ukuphendula ubhubhane lwe-COVID-19, abacwaningi abavela eCenters for Disease Control and Prevention (CDC) bashicilele ucwaningo oluthi ukuxilonga okusekelwe ekhadini kungase. Ingatheleli Cishe izingxenye ezimbili kwezintathu zamacala angenayo izimpawu.
Ucwaningo lwenziwe nezikhulu zezempilo zendawo e-Pima County, Arizona, ezungeze i-Tucson City.Ucwaningo luqoqe amasampula abhanqiwe kubantu abadala abangaphezu kuka-3,400 kanye nentsha.I-swab eyodwa ihlolwe kusetshenziswa ukuhlolwa kwe-Abbott's BinaxNOW, kanti enye yacutshungulwa kusetshenziswa ukuhlolwa kwemolekyuli okusekelwe ku-PCR.
Kulabo abahlolelwe ukuthi bane-HIV, abacwaningi bathola ukuthi ukuhlolwa kwe-antigen kutholwe kahle ukutheleleka kwe-COVID-19 ku-35.8% yalabo abangazange babike noma yiziphi izimpawu, kanye nama-64.2% alabo abathi bazizwa bengaphilile emasontweni amabili okuqala.
Kodwa-ke, izinhlobo ezahlukene zokuhlolwa kwe-coronavirus azikwazi ukuklanywa ngokufana ncamashi ezindaweni nezimo ezahlukahlukene, futhi zingahluka ngokuya ngezinto ezihloliwe kanye nesikhathi sokusetshenziswa.Njengoba u-Abbott (Abbott) esho esitatimendeni, ukuhlolwa kwayo kwenze kangcono ekutholeni abantu abanamandla okusuleleka kakhulu nokudluliswa kwezifo (noma amasampula aqukethe amagciwane aphilayo).
Inkampani iveze ukuthi "i-BinaxNOW inhle kakhulu ekutholeni inani labantu abathelelekayo," okukhomba ababambiqhaza abahle.Ukuhlolwa kuhlonze u-78.6% wabantu abakwazi ukuhlakulela leli gciwane kodwa abangenazimpawu kanye no-92.6% wabantu abanezimpawu.
Ukuhlolwa kwe-immunoassay kuqukethwe ngokuphelele ebhukwini lephepha elilingana nekhadi lesikweletu elifakwe i-swab kakotini futhi ihlanganiswe namaconsi ebhodleleni le-reagent.Uchungechunge lwemigqa enemibala lubonakale lunikeza imiphumela emihle, engemihle noma engavumelekile.
Ucwaningo lwe-CDC luthole ukuthi ukuhlolwa kwe-BinaxNOW nakho kunembe kakhulu.Phakathi kwabahlanganyeli abanezimpawu ababike izimpawu zesifo ezinsukwini ezingu-7 ezedlule, ukuzwela kwakungama-71.1%, okungenye yezindlela ezigunyaziwe zokuhlola ezigunyazwe yi-FDA.Ngesikhathi esifanayo, idatha yomtholampilo ka-Abbott ibonise ukuthi ukuzwela kweqembu elifanayo leziguli kwakungama-84.6%.
Inkampani yathi: "Okubaluleke ngokufanayo, le datha ibonisa ukuthi uma isiguli singenazo izimpawu futhi umphumela ungalungile, i-BinaxNOW izonikeza impendulo efanele 96.9% yesikhathi," inkampani ibhekisela esilinganisweni esithile sokuhlolwa.
I-US Centers for Disease Control and Prevention (CDC) yaseMelika ivumelene nalokhu kuhlolwa, yathi ukuhlolwa kwe-antigen okusheshayo kunezinga eliphansi lemiphumela engelona iqiniso (yize kunemikhawulo uma kuqhathaniswa nokuhlolwa kwe-PCR okwenziwa elabhorathri) ngenxa yokusebenziseka kalula nokushesha. ukucubungula Isikhathi nezindleko eziphansi kuseyithuluzi elibalulekile lokuhlola.Ukukhiqiza nokusebenza.
Abacwaningi bathi: “Abantu abazi umphumela wokuhlola ukuthi une-HIV phakathi kwemizuzu eyi-15 kuya kwengama-30 bangahlaliswa bodwa ngokushesha futhi bangaqala ukulandelela ukuthintana nabo kusenesikhathi futhi basebenza kangcono kunokubuyisela umphumela wokuhlolwa ezinsukwini ezimbalwa kamuva.”"Ukuhlolwa kwe-antigen kusebenza kakhulu."Isikhathi sokushintsha ngokushesha singasiza ukunciphisa ukusabalala ngokuhlonza abantu abangenwe yileli gciwane ukuthi bahlaliswe bodwa ngokushesha, ikakhulukazi uma besetshenziswa njengengxenye yesu lokuhlola i-serial.”
U-Abbott uthe ngenyanga edlule uhlela ukuqala ukunikeza izivivinyo ze-BinaxNOW ngokuqondile ukuze kuthengiwe ukuze kusetshenziswe abahlinzeki bezempilo ekhaya nasezindaweni, futhi uhlela ukuletha ezinye izivivinyo ze-BinaxNOW eziyizigidi ezingu-30 ekupheleni kuka-March, kanye nezinye izigidi ezingu-90 ekupheleni kukaJuni.
Isikhathi sokuthumela: Feb-25-2021